Tagged with Strategy,

Switzerland Recently arrived from Germany, ALK’s new general manager for Switzerland highlights some of the unique features of the Swiss allergology field, and some of the opportunities for ALK to positively impact patients’ lives in the future.   ALK says roughly one in five people suffer from some degree of allergy…

Greece Stavros Theodorakis, managing director of Chiesi Greece & Cyprus and vice president of the Hellenic Association of Pharmaceutical Companies (SFEE), pinpoints the factors that successfully carried the company through the Greek crisis, while highlighting co-branding and co-promotion as the key strategies behind Chiesi’s leading position in the domestic respiratory market.…

Ireland Philip Martin, founder and CEO of Cora Systems in Ireland, explains why his company is ideally positioned to help the pharmaceutical industry increase efficiency and save costs through their agile, flexible and intuitive project management software solutions. “Along with tech improvements, incredible new complexity in how the industry operates has…

Greece Starting as a one-man-show when he began the Greek affiliate in 2009, Orion Pharma’s General Manager, Thanassis Panopoulos discusses the company’s high level of resiliency, the challenges of bringing a Finnish company to Greece, communicating the value of their life-saving products to relevant stakeholders, as well as their objective to…

Switzerland Italian-speaking Swiss canton Ticino outperforms most regions within Europe, yet still lags behind the high-flying cantons of Northern Switzerland. Stefano Rizzi, director of the canton’s economic division, discusses its economic development strategy and the important role that the life sciences sector plays within it. Ticino is the Italian-speaking region of…

Angelini Having joined the company at the onset of its presence in the Greek market, Angelini Pharma Hellas’s General Manager, Panagiotis Giannouleas, speaks about the success of the company’s transitional period, how Angelini is maneuvering through current local uncertainties, and his overarching vision for the future. Mr. Giannouleas, having hailed from…

Switzerland Beat Berger (BB) and Dr Uwe Schmelzer (US) of Swiss API distributor DCS Pharma discuss growth segments in the global generics market, international hotspots, and the benefits of being based in Switzerland.   As an API distributor, what segments of the global generics market do you see the most growth…

Mexico Ricardo Amtmann, President at Laboratorios Sanfer, explains how they have grown their business by 100 percent throughout the last three years and showcases the added value of Sanfer to patients in Mexico and internationally by offering high quality drugs and boosting the sales of in-licensed medicines. Could you introduce yourself…

Switzerland Frederic Bengold, MD of Servier Switzerland, on the affiliate’s main growth drivers, an exciting collaboration with Novartis on heart failure medication, and the intricacies of market access in Switzerland. Could you please start by introducing Servier’s Swiss affiliate? We enjoy a longstanding presence and reputation in Switzerland. The local affiliate…

Switzerland Santen’s Head of EMEA explains why the company established their new regional headquarters in Geneva, Switzerland and highlights the three key strategic pillars on which he bases the growth strategy for the region.   The immense talent present here contributes to the strategic value of the EMEA region, which we…

Switzerland The Chairman of Ferring’s Group Operating Committee and Senior Vice President Europe-Canada elaborates on how Europe can be the thinking engine for global pharmaceutical trends.   Ferring has bundled the European and Canadian markets into one single region. Could you please introduce us to the full scope of your role…

London Among the assorted pharma CEOs and KOLs gathered at the recent Financial Times Pharmaceutical and Biotechnology Conference in London, debate raged on the pros and cons of a pure play strategy, focusing on a few key therapeutic areas, compared to a more diversified approach. If the 1990s and early 2000s, were all…